🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against superbug strains of the bacteria, according to scientists.

An International Public Health Issue

Gonorrhoea infections are on the rise worldwide, with estimates suggesting over 82 million instances annually. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This approval marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

According to findings released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which involves two antibiotics. The study enrolled over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to make available and distribute the drug in many developing nations.

Doctors treating patients have expressed hope. The availability of a easy-to-administer therapy like this is described as a "critical tool" for managing the epidemic. This is considered essential to reduce the burden of the infection for patients and to stop the proliferation of untreatable gonorrhoea around the world.